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Summary 
Right ventricular pacing induces both early and delayed protection against ventricular 
arrhythmias resulting from a prolonged coronary artery occlusion in dogs. The protection, 
however, is pronounced but transient. The early phase of protection disappears within 1-2 
hours but returns 24 h later. This delayed antiarrhythmic protection starts to fade again 48 h 
after the pacing stimulus. The main purpose of the experiments discussed in this thesis was to 
examine whether this delayed phase of the protection can be prolonged by repeating the pacing 
stimulus at the time when the protection has waned (ie. 48 h after one period of pacing). 
Furthermore, we aimed to examine whether this protective effect of right ventricular pacing 
was mediated by nitric oxide and whether this involved induction of nitric oxide synthase. 
Dogs were paced from the right ventricle four times for 5 min at a rate of 220 beats min"1 by 
means of a bipolar pacing electrode. The pacing stimulus was repeated 48 h later. At various 
times, 48, 72 and 96 h after the second pacing stimulus the dogs were reanaesthetised with 
chloralose and urethane, thoracotomised and subjected to 25 min occlusion of the left anterior 
descending coronary artery (LAD). Sham operated dogs served as controls. 
To determine whether nitric oxide plays a role in the delayed protection against arrhythmias 
aminoguanidine (AG) and S-(2-aminoethyl)-methyl-isotiourea (AEST), selective inhibitors of 
the inducible nitric oxide synthase (iNOS), were administered in dogs subjected to one or two 
periods of cardiac pacing. We have also examined the time course of activation of nuclear 
factor K-B (NFKB), a transcription factor involved in the expression of iNOS, in dogs subjected 
to right ventricular pacing (4x5 min) and in rabbits subjected to ischaemic preconditioning (4x5 
min) by brief coronary artery occlusions. 
Repeated right ventricular pacing prolonged the protection against ventricular arrhythmias 
which occurred during a 25 min occlusion of the LAD. Thus, 48 and 72 h after repeated 
cardiac pacing the number of ventricular premature beats and episodes of ventricular 
tachycardia were markedly suppressed, no dog fibrillated during the occlusion, and 50% and 
73% of these dogs survived the reperfiision, respectively. When the time interval between the 
second pacing stimulus and the occlusion is extended to 96h the protection has already faded. 
Administration of aminoguanidine either prior to cardiac pacing or just prior to coronary 
artery occlusion markedly attenuated the protection against ventricular arrhythmias 24h later. 
Similarly, in those repeatedly paced dogs which were treated with AEST before coronary 
artery occlusion the protection was abolished 72h after repeated pacing. 
We have shown that NFKB is activated either by right ventricular pacing in dogs or by 
ischaemic preconditioning in rabbits. The time course of the activation of NFKB differs in these 
two animal models. In dogs right ventricular pacing resulted in activation of NFKB 1 h after 
pacing, but in rabbits ischaemic preconditioning activated the transcription factor 10 min after 
the last preconditioning occlusion. 
We can conclude that repeating the pacing stimulus at a time when the protection has 
already faded prolongs the protection against ischaemia-reperfusion induced ventricular 
arrhythmias for 72 hours but it has waned 96 h later. Nitric oxide may play a role in the 
delayed antiarrhythmic protection since administration of aminoguanidine or AEST, selective 
inhibitors of the inducible nitric oxide synthase, profoundly attenuates the delayed phase of the 
protection induced either by single or repeated pacing stimulus. 
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1. Introduction 
Ischaemic heart disease, myocardial infarction and sudden cardiac death are among the 
main causes of the high mortality rate in developed countries. Certainly, genetic factors 
contribute to the development of these but the risk is increased by other factors, for example 
smoking, cholesterol rich diet and a sedentary lifestyle. Once disease has developed the only 
possibility is treatment for the rest of life. At present we are not aware of a drug which 
completely obviates this condition. 
Myocardial ischaemia is a pathologic state of the myocardium resulting from an insufficient 
blood supply together with a concomitant reduction in oxygen supply. The consequences of 
myocardial ischaemia depend on the duration, as well as on the degree, of an ischaemic insult 
(eg. the coronary artery is occluded totally or partially). The inadequate blood (and oxygen) 
supply to the myocardium results in several metabolic changes, ie. a change from aerobic 
glycolysis to anaerobic glycolysis leading to an accumulation of lactate, a decrease in pH, an 
increase in inorganic phosphates and depletion of ATP. These changes influence the function 
of the contractile elements, and of several proteins as well as ion channels in the membranes 
(Na+/K+ ATPase, Na+/H+ exchanger, K+ATp channel) resulting in complete disturbance of the 
homeostasis of the cell. When the occlusion of the coronary artery is prolonged (30-40 min), 
despite restoration of the blood flow, these alterations become irreversible which ultimately 
lead to myocardial cell death. If the duration of myocardial ischaemia is shorter (ie. 5-15 min) 
the risk of the generation of fatal ventricular arrhythmias and development of necrosis is 
reduced although the contractile function of the heart may remain suppressed for a longer 
period (even days) after complete restoration of myocardial blood flow. 
1.1. Discovery and characteristics of ischaemic preconditioning 
Despite the high risk for the development of ischaemic heart disease and its often fatal 
consequences, intrinsic protective pathways exist to counteract them. It was more than a 
decade ago when Murry and his colleagues reported that in anaesthetised dogs sublethal brief 
periods of ischaemia, which did not in themselves lead to irreversible injury, paradoxically 
protected the heart from a subsequent more prolonged ischemic insult. They termed the 
coronary artery occlusion was repeated within a short time (4x5 min with 5 min reperfusion 
intervals in between) this would lead to a cumulative depletion of the ATP and high energy 
stores, enhance the development of myocardial necrosis. Surprisingly, they found preservation 
of ATP and a delay in cell death during the prolonged (40 min) occlusion of the same coronary 
artery. Thus, myocardial infarct size expressed as the percentage of the area at risk was 
reduced from 30% in controls subjected only to a 40 min occlusion to 7% in preconditioned 
dogs. This marked reduction in infarct size was independent from changes in transmural 
collateral flow. 
Ischaemic preconditioning protects the heart against other severe consequences of 
myocardial ischaemia such as contractile dysfunction or life-threatening ventricular 
arrhythmias. For example, there is a great deal of evidence that preconditioning enhances the 
recovery of contractile function following reperfusion of the ischaemic myocardium (2). There 
is even earlier evidence that short periods of ischaemia protect against ventricular arrhythmias 
resulting from coronary artery occlusion. In 1977, Gulker and colleagues showed that in 
anaesthetised dogs the reduction of the ventricular fibrillation threshold was markedly 
attenuated following repeated coronary artery occlusions (3). In 1983, Barber showed that a 
single 5 min LAD occlusion significantly decreased the number of ventricular ectopic beats 
resulting from a second period of occlusion of the same duration if the reperfusion period 
between the occlusions was 3 min (4). And then in 1987, Shiki and Hearse demonstrated in 
anaesthetised rats that similar short periods (5 min) of coronary artery occlusion reduced the 
incidences of reperfusion induced ventricular tachycardia and fibrillation; ischaemia induced 
arrhythmias were not examined (5). Later, in 1990 Végh and colleagues reported, in 
anaesthetised dogs, that the severity of ventricular arrhythmias occurring during a 25 min 
prolonged ischaemia and subsequent reperfusion was significantly reduced if the dogs had been 
subjected to ischaemic preconditioning by two 5 min occlusions, 20 min previously (6).. 
Several studies have revealed that ischaemic preconditioning of the heart is a general 
phenomenon since tolerance against the severe consequences of myocardial ischaemia can be 
induced in all species examined so far; ie. dogs (1, 6, 7), rats (7-10), pigs (11, 12), rabbits (13-
15), and humans (16, 17). Of great importance is the finding that in patients repeated balloon 
inflations during percutaneous transluminal coronary angioplasty (PTCA) results in similar 
protective effects as ischaemic preconditioning. Thus, the pain, lactate production and ST-
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segment changes were markedly less during the second balloon inflation compared to the first 
indicating that the first ischaemic episode rapidly induced protection, ie. by the time of the 
second ischaemic episode (17). 
There are other sublethal (ischaemic and non-ischaemic) stress stimuli which may lead to 
protection of the heart. These include right ventricular pacing (18, 19), myocardial stretch 
(20), cyclic flow variations (21), hypoxia (22, 23), heat stress (24) and exercise (25, 26). 
1.2. Time dependent characteristic of ischaemic preconditioning 
The cardioprotection associated with preconditioning is extremely powerful but 
unfortunately transient. The degree of the protection depends on the number and duration of 
occlusion periods (5, 27, 28) and on the time interval elapsing between the preconditioning 
stimulus and the prolonged ischaemic insult (7, 28). If the time interval between the 
preconditioning stimulus and the prolonged coronary artery occlusion is extended to 30 min or 
1 h the protection, for example against ischaemic damage or ventricular arrhythmias, is largely 
attenuated or abolished (7, 29-33). For example, rapid cardiac pacing (4x5 min) in dogs 
induces marked antiarrhythmic protection when myocardial ischaemia is initiated 5 min after 
pacing but the protection is not apparent if the time interval between the pacing stimulus and 
the occlusion is extended to 15 min, 1 h or 6 h (30). In pigs, rapid ventricular pacing (30 min) 
induces protection against ischaemic damage if the prolonged ischaemia is initiated 
immediately but it is slightly reduced 15 min later (34). Similarly, in conscious rabbits cardiac 
pacing results in protection against consequences of a subsequent ischaemic episode, as shown 
by reductions in ST-segment elevation and in the increase in left ventricular end-diastolic 
pressure (35). The reduction in the severity of ischaemia is completely lost if the time interval 
between the preconditioning stimulus and the subsequent ischaemia is extended to 30 min (35). 
Interestingly, in anaesthetised rabbits, the commencement of a second 5 min occlusion at the 
time when the protection resulting from a previous preconditioning stimulus is lost can restore 
the protection against infarction (36). In contrast, repeating the preconditioning stimulus in 
pigs 1 h later fails to renew the protection against ischaemic damage (29). It is possible to 
enhance this fading protection pharmacologically. In rabbits the cardioprotection induced by 
short coronary artery occlusions waned after 2 h but could be enhanced at this time by the 
administration of acadesine, a drug which is believed to act by increasing the level of adenosine 
in the myocardium (32, 33). 
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The cardioprotection which disappears within 1-2 hours, and which is termed now as 
"classical preconditioning", returns 24 h after the preconditioning stimulus. This delayed phase 
of protection was first reported by Yamashita and colleagues in 1992 (37) and later by Kuzuya 
and colleagues in 1993 (38). In their studies dogs were subjected to ischaemic preconditioning 
and the extent of the infarction was examined immediately and 3 h, 12 h and 24 h later. They 
found that there was a significant reduction in infarct size when the sustained occlusion 
followed the preconditioning stimulus either immediately or 24 h later but not at intermediate 
times (3 h and 6 h). In the same year Marber and colleagues reported that the extension of 
myocardial necrosis was significantly smaller in rabbits subjected to ischaemic preconditioning 
or heat stress 24 h previously (39). Similarly, in anaesthetised dogs the severity of ventricular 
arrhythmias during a 25 min coronary artery occlusion and following reperfusion was 
significantly reduced if the dogs had been subjected to right ventricular pacing 20-24 h 
previously (30, 40, 41). In conscious rabbits right ventricular pacing (ten times for 5 minutes) 
induced protection against consequences of a subsequent test (pacing-induced) ischaemia 
which was present 24 and 48 h after pacing but not 72 h later (35). Delayed protection induced 
by short coronary artery occlusions against ischaemic damage in anaesthetised rabbits was 
more prolonged; it lasted for 72 hours (42-44). Similarly, preconditioning in conscious pigs 
decreased the degree of contractile dysfunction (myocardial stunning) 24 h later; this 
protection also lasted for 72 h (45, 46). In dogs the pronounced protection against ischaemia 
and reperfusion induced ventricular arrhythmias faded by 48 h and was lost 72 h after the 
pacing stimulus (30). 
1.3. Possible mechanisms involved in the cardioprotective effects of ischaemic 
preconditioning 
Since the protection of the heart to a sustained ischaemic insult afforded by various sublethal 
preconditioning stimuli is so powerful it would be important to explore the underlying 
mechanisms in the hope of developing new therapeutic interventions. Although several 
hypotheses have attempted to explain both the early and the delayed cardioprotective effects of 
preconditioning the precise mechanisms of the protection are still unclear. There is a strong 
evidence that the release of endogenous myocardial protective substances such as adenosine, 
bradykinin, prostacyclin and nitric oxide deriving from the vascular endothelium and also from 
cardiac myocytes are involved both in the early and the delayed phase of cardioprotection (47). 
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One of the endogenous substances which is released abundantly from the ischaemic 
myocardium is adenosine. Several studies have demonstrated the cardioprotective effects of 
adenosine in the ischaemic heart. Thus, adenosine can suppress arrhythmias (48, 49), limit 
infarct size (14) and decrease contractile dysfunction (50). Adenosine most probably plays a 
role as a trigger of the protection against ischaemic damage via activation of Ai receptors (14, 
51). The evidence for the involvement of Ai receptors in this form of cardioprotection comes 
from studies which demonstrated that the infarct size resulted from prolonged ischaemia was 
markedly reduced by prior administration of an Ai selective agonists such as R-phenylisopropyl 
adenosine (R-PIA) or 2-chloro-N6-cyclopenthyl-adenosine (CCPA) (52). Adenosine infusion 
in blood-perfused rabbit hearts mimicked the effect of ischaemic preconditioning against 
ischaemic damage; the limitation of infarct size was similar to that found afrer ischaemic 
preconditioning (53). However, the "in vivo" experiments were not able to prove that 
adenosine plays a trigger role in the infarct size limiting effect of preconditioning (54). 
The other endogenous protective substance which might be involved in the cardioprotective 
effects of ischaemic preconditioning is bradykinin. It is well established that bradykinin is 
generated and released in the very early stage of ischaemia by activation of an acid optimum 
kininogenase enzyme (55). Furthermore, bradykinin infused into a small branch of the LAD 
markedly reduced the ischaemia-induced ventricular arrhythmias in anaesthetised dogs (56). 
There is some evidence that bradykinin is involved in the protective effect of ischaemic 
preconditioning since icatibant (HOE 140), a selective antagonist of bradykinin at B2 receptors, 
abolished the antiarrhythmic effect of preconditioning induced either by short coronary artery 
occlusions or cardiac pacing in anaesthetised dogs (57, 58). Bradykinin proved to be also 
involved in the infarct size limiting effect of ischaemic preconditioning and this effect could be 
reversed by icatibant (59, 60). 
There is some evidence that bradykinin stimulates the generation of nitric oxide and 
prostacyclin (61, 62). The antiarrhythmic effect of bradykinin was largely attenuated by 
inhibiting the generation of nitric oxide with L-nitroarginine methyl esther (L-NAME) which 
indicates a bradykinin-induced nitric-oxide mediated mechanism in the antiarrhythmic effect of 
preconditioning (63). Furthermore, inhibition of the formation of nitric oxide with L-NAME 
(64) and cGMP with methylene blue (65) markedly attenuates the antiarrhythmic protection 
induced by ischaemic preconditioning. According to these findings a hypothesis for the 
antiarrhythmic effect of ischaemic preconditioning is that bradykinin triggers the release of 
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nitric oxide from the vascular endothelium which diffuses into the cardiac myocytes and 
increases the level of cGMP level by stimulating the soluble guanylate cyclase enzyme. 
1.4. Aims of the studies 
1. The main objective of the studies presented in this thesis was to determine whether the 
marked delayed antiarrhythmic protection could be prolonged by repeating the pacing stimulus 
at the time when the protection from the previous preconditioning stimulus had faded. 
2. A second series of experiments aimed to determine whether the mechanism of this 
marked early and delayed antiarrhythmic protection involves nitric oxide and prostacyclin. For 
this purpose experiments were designed to investigate: 
a, the involvement of nitric oxide and prostacyclin in classical preconditioning by 
simultaneous blockade of the L-Arg/NO and cyclooxygenase pathways, 
b, the involvement of nitric oxide in the delayed antiarrhythmic protection induced by 
„single" or repeated periods of cardiac pacing by administration of selective inhibitors 
of the inducible nitric oxide synthase, 
c, the time course of the activation of nuclear factor K-B (NFKB), a transcription 
factor which is involved in the expression of iNOS, both in dogs subjected to right 
ventricular pacing and in rabbits subjected to ischaemic preconditioning by coronary 
artery occlusions. 
2. Materials and methods 
2.1. Animals 
Experiments were carried out in adult, mongrel dogs of both sexes with a body weight in 
excess of 17 kg. The dogs were allowed to access to food and water ad libitum until starting 
the experiments. All animals received humane treatment according to the Guide for the care 
and use of laboratory animals published by National Institute of Health of the USA (1985) 
and by a local university policy. 
2.2. Surgical preparations 
Dogs were anaesthetised with a mixture of chloralose and urethane (60 mg kg'1 and 200 mg 
kg'1, respectively), ventilated with room air using a Ugo respirator (Hugo Sachs Elektronik, 
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Germany) at a sufficient rate and volume to maintain the arterial blood gases and pH within 
normal limits (p02: 80-105 Hgmm, pC02: 35-54 Hgmm, pH: 7,36-7,44). The body 
temperature was monitored from the oesophagus and maintained at 37+0.5 °C by using a 
heating pad. The animals were thoracotomised in the fifth intercostal space and the left anterior 
descending coronary artery (LAD) was prepared for occlusion proximal to the first main 
diagonal branch (Figure 1). Myocardial ischaemia was induced by a 25 minute occlusion of the 
LAD after which the occlusion was rapidly released. In some experiments drugs were infused 
intracoronarily into a small side branch of the LAD, proximal to the occlusion site (Figure 1). 
To measure the basic heamodynamic parameters polyvinyl catheters were introduced into the 
right femoral artery for monitoring the arterial blood pressure (systolic: SABP, diastolic: 
DABP), to the left ventricle via the left carotid artery to measure the left ventricular systolic 
(LVSP) and end-diastolic (LVEDP) pressures and the maximal positive and negative dP/dt, 
and into the right femoral vein for administration of anaesthetics and drugs. Haemodynamic 
parameters were measured by means of pressure transducers (P23XL, Hugo Sachs Elektronik, 
Germany). To evaluate the severity of myocardial ischaemia a composite electrode was sutured 
to the risk area of the left ventricle; this composite electrode also contained four unipolar 
electrodes (66, 67). By means of this electrode changes in epicardial ST segment elevation and 
the degree of inhomogeneity of electrical activation were recorded. The composite electrode 
gives a summarised recording of R waves from 30 epicardial measuring points. In the normal 
adequately perfused and oxygenated heart these sites in the left ventricular wall are activated at 
almost the same time giving rise to a large spike on the ECG. During ischaemia the adjacent 
fibres are not activated simultaneously and, due to the inhomogeneity of conduction, 
fractionation and widening of the R wave appears. The inhomogeneity of electrical activation 
is expressed as the greatest delay (ms) in the activation within the ischaemic area under the 
composite electrode. All of these parameters, together with the limb lead electrocardiogram, 
were recorded on a Graphtec Thermal Array Recorder (Hugo Sachs, Germany). 
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EP1CARD1AL ECG 
Figure 1. The experimental model in anaesthetised dogs for the measurement of 
haemodynamic parameters, changes in epicardial ST-segment elevation and degree of 
inhomogeneity of electrical activation and for the assessment of ventricular arrhythmias. 
2.3. Evaluation of ventricular arrhythmias 
Ventricular arrhythmias were evaluated by a method largely based on the principles laid 
down by the Lambeth' Convention (68). Thus, the number of ventricular premature beats 
(VPBs) was determined without distinction between couplets and salvos which were assessed 
as single ventricular ectopic beats. The number of episodes of ventricular tachycardia (VT) in 
each dog, the incidences of ventricular tachycardia and ventricular fibrillation (VF) were also 
determined both during the occlusion period and following the initiation of reperfusion. Those 
dogs which fibrillated during occlusion or reperfusion were not defibrillated. Survival indicates 
those dogs which were in sinus rhythm without any ischaemic alterations on the epicardial or 
limb lead ECGs for at least 10 minutes after reperfusion. 
2.4. Determination of the area at risk 
At the end of the experiments the heart was excised and the LAD suture was again 
tightened. Methylene blue dye was infused into the occluded coronary artery distal to the site 
of occlusion. The risk (dyed) area was expressed as the percentage of the mass of the left 
ventricular wall together with the septum. 
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2.5. Experimental protocols 
2.5.1. Protocol to examine the role of nitric oxide and prostacyclin in classical 
preconditioning 
CONTROL 
n=16 
PC. 
OCCLUSION REPERFUSION 
0 0 
PC, 
PC 
11=22 
PC+MF 
+LNAME 
n=9 
MF+LNAMF. 
+PC 
•1=10 
MF, l.v. LNAME, i.e. 
i I 
MF, i.v. LNAME, i.e. 
I i 
I 
-30 
liH—i—i—r 
-10 o 5 
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Time (min) 
Figure 2. 
Dogs were preconditioned by two 5 min occlusion of the LAD with 20 min reperfusion 
period in between (PC, n=22). Myocardial ischaemia was induced by a 25 min occlusion of the 
same artery 20 min after the second preconditioning occlusion. Control dogs were subjected 
only to a 25 min coronary artery occlusion followed by reperfusion (n=16). In one group of 
preconditioned dogs sodium meclofenamate (MF, a cyclooxygenase (COX) inhibitor) was 
administered intravenously in a dose of 2 mg kg"1 followed by infusion of L-nitroarginine 
methyl esther (L-NAME, a nitric oxide synthase (NOS) inhibitor) intracoronarily in a dose of 5 
mg kg'1 30 min and 20 min before preconditioning, respectively (n=9). In one group of 
preconditioned dogs meclofenamate and L-NAME were administered 15 and 10 min before 
the prolonged ischaemic insult, respectively (n=9). 
2.5.2. Protocol for the determination of the role of NO in delayed protection induced by a 
single cardiac pacing 
SHAM CONTROL (SC5) 
n=12 
PACED (P) 
n=13 
P. P« P. P« 
H M H M 
OCCLUSION REPERFUSION 
i » 
AG+P24 
n=12 
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n=9 
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n=8 
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f t 
M M M M 
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AG infusion 
o . 
AG infusion 
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-30 0 5 15 25 3S 24h -30 0 25 
AG : aminoguanidine P : Pacing, 5 min 
Figure 3. 
For the commencement of cardiac pacing a bipolar pacing electrode (Cordat F4) was 
introduced under light pentobarbitone anaesthesia into the right ventricle via the right jugular 
vein. The correct position of the electrode was confirmed by recording the endocardial 
electrocardiogram from the pacing electrode and monitored continuously during the 
procedure. Dogs were paced four times for 5 minutes at a rate of 220 beats min"1. Changes in 
mean arterial blood pressure (MABP) were registered by means of a catheter introduced into 
the left carotid artery. During pacing ST-segment changes on the endocardial ECG and limb 
lead ECG were also recorded. 24 h later, these preconditioned dogs (P, n=13) were re-
anaesthetised with a mixture of chloralose and urethane, thoracothomised and the LAD was 
occluded for 25 minutes followed by rapid reperfusion. In some paced dogs aminoguanidine 
(AG) was administered intravenously in a dose of 50 mg kg'1 either 30 minutes prior to pacing 
(AG+P24, n=12), or 30 minutes prior to the prolonged occlusion of the LAD but 24 h after 
right ventricular pacing (P24+AG, n=9). The sham-operated dogs served as controls. In these 
12 dogs (SC5) the bipolar pacing electrode and the polyvinyl catheter were introduced into the 
right ventricle and the left carotid artery but these dogs were not paced. 24 hours later these 
dogs were re-anaesthetised and subjected to myocardial ischaemia followed by reperfusion. 
Another 8 dogs which were not paced but given aminoguanidine 30 minutes before coronary 
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artery occlusion served as the aminoguanidine control group to determine whether AG itself 
modified the severity of ventricular arrhythmias. 
2.5.3. Protocol for evaluation of the prolongation of delayed antiarrhythmic protection 
induced by repeated cardiac pacing; the role of NO 
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Figure 4. 
This study was designed to examine whether the delayed antiarrhythmic protection resulting 
from right ventricular pacing could be prolonged by repeating the pacing stimulus at a time 
when the protection was no longer apparent, ie. 48h after one period of cardiac pacing (30). In 
these experiments dogs underwent sterile surgical intervention under light pentobarbitone 
anaesthesia. Then a bipolar pacing electrode was introduced into the right ventricle and a 
polyvinyl catheter was led into the left carotid artery to measure changes in mean arterial blood 
pressure during pacing. The animals were paced four times for 5 min at a rate of 220 beats min' 
1 and left to recover from anaesthesia for 48 h. After recovery the dogs were repaced in the 
same manner as described above and left to recover for various time intervals. 48, 72 or 96 h 
after the second pacing procedure dogs were re-anaesthetised with a mixture of chloralose and 
urethane, thoracotomised and the LAD was prepared for occlusion. Myocardial ischaemia was 
induced by a 25 min occlusion of the coronary artery followed by reperfusion. Under 
pentobarbitone anaesthesia sham-operated control dogs were subjected to the same surgical 
interventions but the dogs were not paced, although they were re-anaesthetised with 
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pentobarbitone 48h later. After 48h or 72h recovery they were subjected to coronary artery 
occlusion for 25 min. 
In the second part of the study, in repeatedly paced dogs S-(aminoethyl)-methyl isothiourea 
(AEST, 2 mg kg"1) was given starting the infusion 90 min before occlusion of the LAD. To 
determine the effect of AEST on ventricular arrhythmias 8 sham-operated dogs, without 
repeated pacing, were given AEST 90 min before coronary artery occlusion. 
2.6. Electromobility shift assay for determinaion of the activation of nuclear factor K-B 
Experiments were designed to determine whether nuclear factor K-B (NFKB), the 
transcription factor involved in the expression of inducible nitric oxide synthase, was activated 
after preconditioning induced by right ventricular pacing. These studies were performed at the 
Department of Pharmacology and Pharmacotherapy of the Albert Szent-Györgyi Medical 
University, in Szeged and at the Hatter Institute and Centre for Cardiology of University 
College London, in London. Dogs were paced four times for 5 min through the right ventricle 
by means of a pacing electrode. At various times, 15 min, lh and 24h later, the hearts were 
excised and samples from the left ventricle were obtained, frozen in liquid nitrogen and stored 
at -80°C until used. In another series of the experiments male rabbits were used with a body 
weight of 2.7 kg. These were preconditioned by four periods of 5 min occlusion of the LAD 
separated by 10 min reperfusion periods. 10 min, lh, 3h after last reperfusion the hearts of 
these animals were excised and samples from the risk area of the left ventricle were frozen in 
liquid nitrogen and stored at -80°C until used. Nuclear proteins were purified by the method of 
Schreiber with some modifications (69). Briefly, 0.1-0.15 g of heart tissue were homogenised 
and centrifiiged in 1 ml ice-cold PBS solution. The supernatant was discarded and the pellet 
was suspended in 400 pi ice-cold buffer A (10 mM N-(2-hydroxyethyl)piperazine-N-2-
ethansulfonic acid (HEPES), 10 mM KC1, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM 
dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), leupeptin, aprotinin, 
pH=7.9) and incubated for 15 min on ice. Nonidet P40 was added to the homogenate, 
vortexed for 45 s, incubated for 5 min and centrifiiged at 14000 rpm for 1 min at 4 °C. The 
supernatant with the cytosolic protein fraction was stored at -80°C and the pellet of nuclei was 
resuspended in 400 \ü ice-cold buffer C (20 mM HEPES, 400 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1 mM DTT, 1 mM PMSF, pH=7.9) and rocked on a shaking platform for 30 min on 
ice. The samples were then centrifiiged for 15 min at 14.000 rpm at 4°C. The supernatant was 
collected as the nuclear protein fraction and stored at -80 °C. 
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Activation of NFKB was examined by the ElectroMobility Shift Assay (EMSA). Nuclear 
proteins (20 pg) were combined with poly dldC (0.2 pg pi"1 ) to reduce the non-specific DNA 
binding, binding buffer (4% glycerol, 1 mM EDTA, 10 mM Tris pH=7.5, 0.1 M NaCl, 10 pg 
BSA, 5 mM DTT, 1 mM MgCl2) and labelled oligonucleotide (5' AGT TGA GGG GAC TTT 
CCC ACG C 3') in a total volume of 15 pi, incubated for 30 min at room temperature and 
resolved on a 5% non-denaturing polyacrilamide gel. This gel was pre-run for 3 h at room 
temperature in 0.25X tris(hydroxymethyl)aminoethane/ boric acid/ EDTA buffer (TBE) at 
125V. After running for 3h the gels were dried at 80 °C without vacuum for an hour and 
exposed to Kodak film at -70 °C. Oligonucleotide was 5' end-labelled as dsDNA with [y-
32P]ATP using T4 polynucleotide kinase. In competition assay unlabelled cold probe was also 
added in excess to the binding reaction and it was incubated for 10 min before adding labelled 
probe to the reaction. 
2.7. Statistical analysis 
The data are expressed as mean ± s.e.m. and differences between means were compared by 
analysis of variance (ANOVA) or by Student's t test. A one-way ANOVA was used to 
compare differences in haemodynamic parameters. Mann-Whitney rank sum test was used for 
analysis of VPBs and episodes of VT, and Fisher exact test was used for comparison of the 
incidences of VT, VF and survival. Differences between groups was considered significant 
when P <0.05. 
2.8. Chemicals 
Nembutal was purchased from Phylaxia-Sanofi, a-Chloralose, Uretane, Sodium 
Meclofenamate, L-Nitro Arginine Methyl Esther, Aminoguanidine Hemisulphate, Methylene 
blue dye, EDTA, EGTA, DTT, PMSF from Sigma, S-(aminoethyl)-Methyl Isothiourea a kind 
gift from Csaba Szabo, NFKB oligonucleotide from Santa Cruz, T4 polynucleotide kinase from 
Promega, [y-32P]ATP, aprotinin, leupeptin from ICN, HEPES, KC1, NaCl from BDH 
laboratory supplies. 
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3. Results 
3.1. Prolongation of delayed antiarrhythmic protection by repeating the pacing stimulus 
3.1.1. Haemodynamic and electrocardiographic effects of repeated cardiac pacing 
Right ventricular pacing increased heart rate (HR) from a mean of 169±4 beats min"1 to 220 
beats min"1 and transiently decreased (approximately 35%) mean arterial blood pressure 
(MABP) immediately after initiation of the pacing stimulus (Table 1). When the pacing 
stimulus was repeated 48 hours later a significant decrease was found in baseline MABP and 
HR, but changes in these parameters were similar on day three (Table 1). 
Table 1. Changes in heart rate and mean arterial blood pressure during pacing 
1. day 3. day 
before pacing after pacing change before pacing after pacing change 
* HR (beats min"1) 169±4 220±0 51±4* 155+4 f 220±0 75±8 
MABP (mmHg) 141+4 112±6 29±4 * 110+41 82±4 18+5 * 
* P < 0.05 vs. baseline f P < 0.05 vs. 1. day baseline 
Table 1. Haemodynamic parameters during pacing on day one and day three in repeatedly 
paced dogs. All individual data in the these groups were combined into one group because 
there was no difference between them. HR: heart rate (beats min '), MABP: mean arterial 
blood pressure (mmHg). 
8 1 1. day 3. day 
4 " 
H on 
•S 2 
* * * _ L 
• 
baseline PI P2 P3 P4 baseline PI P2 P3 P4 
Figure 5. Changes in endocardial ST segment elevation recorded from the right ventricle 
(mV) immediately after cessation of pacing in repeatedly paced groups on day 1 and day 3. * 
P<0.05 vs. baseline. 
Rapid cardiac pacing resulted in a transient, but significant, elevation in the endocardial ST-
segment (a sign of ischaemia induced by pacing) from a mean baseline of 1.1 ±0.5 mV to 
3.2±0.6 mV after cessation of the first pacing stimulus, to 3.3+0.8 mV after both second and 
third pacing stimuli, and to 3.310.5 mV after the fourth pacing stimulus. ST-segment elevation 
was slightly higher when the pacing stimuli were repeated 48 h later; it was increased from 
1.610.4 mV to 4.511 mV, 4.211.2mV, 4.911.5mV, respectively after termination of the pacing 
stimuli. 
All haemodynamic and electrocardiographic changes returned to the baseline values within 
1-2 minutes after cessation of pacing. 
3.1.2. Haemodynamic effects of coronary artery occlusion 
Coronary artery occlusion resulted in slight or significant decreases in systolic, diastolic and 
mean arterial blood pressures, left ventricular systolic pressure and in positive and negative 
dP/dt and an increase in left ventricular end-diastolic pressure within a few minutes of the 
initiation of the coronary artery occlusion (Table 2). Changes in these haemodynamic 
parameters were similar in sham-operated dogs and in those dogs that had been paced 
repeatedly 48, 72 or 96 h previously. 
Table 2 Haemodynamic parameters during LAD occlusion in chloralose and urethi me anaesthetise id dogs 
Sham Control RP48 RP72 RP96 
baseline change baseline change baseline change baseline change 
SABP (mmHg) 131±6 -1013 * 139±5 0.512 14919 -1114* 11814 -714 
DABP (mmHg) 89±4 -7±3 * 93±4 0.212 8817 -513 7615 -913* 
MABP (mmHg) 103±4 -8±3 * 109+3.5 0.312 10917 -713 9014 -812 * 
LVSP (mmHg) 128±7 -11±4 * 13616 112 131111 -713* 11214 -514 
LVEDP (mmH)g 9±2 -3.4±2 712 511.5 » 1112 0.812 811 511 « 
+dP±dt (mmHg s'1) 2237±214 -360±219 19981163 -144180 29361 265 -3551304 28201454 -5631348 
-dP±dt (mmHg s'1) 3004±267 -3261107 * 22471313 -142198 32951191 -5331216 * 28501126 -3431121 
HR (beats nun'1) 148±5 5.4±1.5 » 16419 4.211.4 * 146110 0.611 14915 0.611 
Table 2. Changes in haemodynamic parameters during coronary artery occlusion in sham 
control and repeatedly paced dogs (RP48, RP72, RP96). SABP: systolic arterial blood 
pressure, DABP: diastolic arterial blood pressure, MABP: mean arterial blood pressure, 
LVSP: left ventricular systolic pressure, LVEDP: left ventricular end diastolic pressure, HR: 
heart rate, + dP/dt: positive left ventricular dP/dt, -dP/dt: negative left ventricular dP/dt. 
P<0.05 vs. baseline, data are expressed as meanisem. 
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3.1.3. Ischaemia and reperfusion induced ventricular arrhythmias in sham control dogs and 
in dogs subjected to repeated pacing 
Right ventricular pacing results in a marked protection against ischaemia and reperfusion-
induced ventricular arrhythmias, when the LAD was occluded 24 h after the pacing stimulus 
(30, 40, 41). However, this protection has faded after 48 h or is lost after 72 h (Figure 6). 
SINGLE PACED REPEATEDLY PACED 
V F S U R V I V A L V F S U R V I V A L 
100 - i 
SCI 24h 48h 72h SCI 24h 48h 72h SC4 48h 72h 96h SC4 48h 72h 96h 
occ lus ion | | o c c l u s i o n - r e p e r f u s i o n 
Figure 6. The incidence of ventricular fibrillation (VF) and survival during occlusion and 
after reperfusion in sham control dogs (SCI, SC4) and in dogs subjected to a period of single 
pacing (4x5 min) 24, 48 and 72 h before coronary artery occlusion and in repeatedly paced 
dogs subjected to LAD occlusion 48, 72 and 96 h after the second pacing stimulus. (Data of 
SCI and single paced groups taken from Ref 30). * P<0.05 vs. sham control. 
Since in the present study there was no significant difference between the two time-matched 
sham-control groups (96h, n=l l and 120h, n=10, Figure 4) we combined these animals in one 
group (SC4, n=21). In this combined sham-control group nearly all dogs exhibited severe 
ventricular arrhythmias following coronary artery occlusion. The number of ventricular 
premature beats (VPBs; 231 ±69) and the number of episodes of ventricular tachycardia 
(VTepisodes; 4.4±1.6) were high in these animals. VT occurred during the occlusion period in 
14 out of 21 sham control dogs, 7 dogs fibrillated (33%) during the occlusion period and 10 
out of the 14 remaining dogs which survived the occlusion fibrillated following reperfusion. 
Thus, only 4 out of 21 sham control dogs survived the combined occlusion-reperfusion insult 
(Figure 7). 
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Figure 7. Distribution of ventricular arrhythmias: ventricular ectopic beats (VPBs, 
indicated as light grey), ventricular tachycardia (VT, indicated as dark grey), and ventricular 
fibrillation (VF, indicated as black) in sham operated control dogs (a, panel), and repeatedly 
paced dogs subjected to a 25 min occlusion of the LAD 48, 72 or 96 h later (b, c, d, panels). 
All arrhythmia parameters were markedly suppressed in those dogs which were subjected to 
repeated pacing 48 and 72 h previously. For example, few ectopic beats (VPBs: 95+39; 
100±47, respectively) occurred in these dogs; the incidence of VT was low (20% and 18%, 
respectively) and no dog fibrillated during the occlusion period in these two repeatedly paced 
groups. Repeated cardiac pacing significantly increased survival from the combined ischaemia-
reperfusion insult 48 and 72 h later, 50% and 73% of these dogs survived, respectively (Figures 
6 and 7). 
When the time interval between the second pacing stimulus and the occlusion was extended 
to 96 hours the antiarrhythmic protection faded. Although the number of ectopic beats and VT 
episodes was still suppressed, 45% of the dogs fibrillated during the occlusion and only 2 out of 
9 dogs survived the reperfusion. 
3.1.4. Changes in the indices of ischaemia severity 
The severity of myocardial ischaemia was expressed by changes in epicardial ST-segment 
elevation and in the degree of inhomogeneity of electrical activation within the ischaemic area. 
In the sham control group pronounced epicardial ST-segment elevation developed within 3 
min of the occlusion, reached a maximum at 5 min and remaining stable during the rest of the 
occlusion period. In those dogs which were previously subjected to repeated pacing, the 
ischaemia-induced epicardial ST-segment elevation was significantly reduced; this was 
especially marked in those dogs which were subjected to repeated pacing 48 or 72 h previously 
(Figure 8). Changes in the degree of electrical inhomogeneity were similar to changes in 
epicardial ST-segment elevation. Thus, compared to the sham controls, in dogs paced 
repeatedly 48, 72 h and even 96 h before the occlusion the degree of inhomogeneity was 
significantly reduced over the entire occlusion period (Figure 9). 
Time (mill) 
O SC4 • RP48 • RP72 + RP96 
Figure 8. Changes in epicardial ST segment elevation (mV) during 25 min occlusion of the 
left anterior descending coronary artery in sham control dogs (SC4) and in repeatedly paced 
dogs (RP48, RP72, RP96). *P<0.05 vs. sham controls. 
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Figure 9. Changes in the degree of inhomogeneity of electrical activation (ms) during 25 
min occlusion of the left anterior descending coronary artery in sham control dogs (SC4) and 
in repeatedly paced dogs (RP48, RP72, RP96). *P<0.05 vs. sham controls. 
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3.2. Evidence for the role of nitric oxide and prostacyclin in classical preconditioning 
3.2.1. Haemodynamic effects of administration of meclofenamate and L-NAME 
Intravenous administration of meclofenamate had no significant haemodynamic effects 
(Table 3). However, infusion of L-nitroarginine methylesther (L-NAME) into a small branch 
of the left anterior descending coronary artery significantly increased arterial blood pressure 
(SABP, DABP, MABP), left ventricular systolic pressure (LVSP) and significantly decreased 
heart rate (HR). There were no marked changes in left ventricular end-diastolic pressure, in 
positive or negative LVdP/dt. 
Table 3. Haemodynamic effects of meclofenamate and L-NAME 
Pre-meclofenamate change Pre-L-NAME change 
SABP (mmHg) 121±8 6±2 12518 1613* 
DABP (mmHg) 78±4 4±3 8015 2612* 
MABP (mmHg) 92±5 5 ±2 9515 2212* 
LVSP (mmHg) 125±7 5 ±2 12917 1813* 
LVEDP (mmHg) 6±1 0 711 I i i 
+dP/dt (mmHg s"1) 27461162 118178 28171204 2181126 
-dP/dt (mmHg s1) 2560±114 192166 26741100 1711119 
HR (beats min"1) 151±9 211 153110 -812* 
Table 3. Haemodynamic changes induced by meclofenamate (2 mg kg1) and L-NAME (5 
mg kg'1) in chloralose-urethane anaesthetised dogs. * P<0.05 vs. baseline. 
3.2.2. The severity of ventricular arrhythmias during the preconditioning procedure induced 
by brief coronary artery occlusions 
Occlusion of the LAD proximal to the first main diagonal branch in dogs (Figure 1) results 
in a 35-40% area at risk and leads to the occurrence of ventricular arrhythmias such as 
ventricular ectopic beats, tachycardia and even fibrillation. These arrhythmias appear within a 
few minutes after ligation of the coronary artery. When dogs are preconditioned by brief 
coronary artery occlusion usually 25 % of these dogs fibrillate either during the first 
preconditioning occlusion or immediately after reperfusion of the ischaemic myocardium 
(Figure 10). In the presence either of L-NAME or sodium meclofenamate given prior to 
preconditioning, the incidence of VF during the preconditioning procedure was increased to 
30% or 45%, respectively. However, when both meclofenamate and L-NAME were given 
together prior to the first 5 min occlusion 78% of the dogs fibrillated during the 
preconditioning procedure (Figure 10). 
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Figure 10. The incidence of ventricular fibrillation (VF) during the preconditioning 
procedure (PC), in preconditioned dogs treated with L-NAME (L-NAME+PC) or sodium 
meclofenamate (MF+PC), and in dogs in which both meclofenamate and L-NAME were 
administered prior to the preconditioning procedure (MF+L-NAME+PC). * P<0.05 vs PC. 
3.2.3. The severity of ventricular arrhythmias during prolonged occlusion in preconditioned 
dogs treated with L-NAME and meclofenamate 
Ischaemic preconditioning by brief coronary artery occlusions protects the heart against 
those arrhythmias which occur during the subsequent prolonged ischaemic insult (7). Thus, 
compared to the control group in preconditioned dogs the number of ventricular premature 
beats (VPBs, 72±21 vs. 439±72, P<0.01) and episodes of ventricular tachycardia (VT, 1.1±0.5 
vs. 7.6±2.1, P<0.01) was significantly decreased during prolonged occlusion (Figure 11). 
Furthermore, preconditioning markedly reduced the incidences of the more malignant 
ventricular arrhythmias such as VT or VF both during occlusion and reperfusion. Thus, in the 
control group 42% of the dogs fibrillated during the occlusion period and those which survived 
the prolonged ischaemia fibrillated after reperfusion (Figure 12). In contrast, in the 
preconditioned group no dog fibrillated during occlusion, and only 11 out of 22 dogs fibrillated 
after reperfusion. Thus, 50% of the preconditioned dogs survived the combined occlusion-
reperfusion insult (Figure 12). 
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Figure 11. The number of ventricular premature beats (VPBs) and episodes of ventricular 
tachycardia (VT) during a 25 min coronary artery occlusion in control, preconditioned (PC), 
and also those preconditioned dogs which were treated with MF and L-NAME before or after 
the preconditioning procedure. * P<0.05 vs. control group, f P<0.05 vs. PC group. 
When both meclofenamate and L-NAME were given together before the preconditioning 
procedure the number of VPBs and the number of episodes of VT were significantly increased 
(72+21 vs. 301+134, 1.1+0.5 vs. 17.5+4.5, P<0.01) compared to the dogs preconditioned 
without administration of drugs (Figure 11). However, when meclofenamate and L-NAME 
were administered after preconditioning, but prior to the prolonged occlusion, the number of 
VPBs and episodes of VT during sustained ischaemia was still markedly reduced compared to 
the controls (118+74 vs. 439±72, P<0.05, and 2.6±2.2 vs. 7.6+2.1, Figure 11). Dual blockade 
of cyclooxygenase and nitric oxide synthase enzymes before ischaemic preconditioning resulted 
in high incidences of VT (100%) and VF (50%) during occlusion and no dog survived the 
combined occlusion-reperfusion insult in this group (Figure 12). In dogs treated with both 
meclofenamate and L-NAME after preconditioning, but before sustained ischaemia, the 
number of VPBs and episodes of VT was still markedly suppressed similar to that seen in 
preconditioned dogs, but the incidences of VT and VF during occlusion and after reperfusion 
were as the same as in the control group (Figure 12). 
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Figure 12. The incidences of VT, VF and survival during coronary artery occlusion and 
reperfusion in control, preconditioned dogs (PC) and in those preconditioned groups in which 
the animals were treated with MF and L-NAME either before or after the preconditioning 
procedure. * P<0.05 vs. control group, f P<0.05 vs. PC group. 
3.2.4. The effect of meclofenamate and L-NAME on the severity of myocardial ischaemia 
induced by coronary artery occlusion 
Compared to the control group preconditioning markedly reduced the severity of ischaemia 
as shown by a significant decrease in epicardial ST-segment elevation (Figure 13) and in the 
degree of inhomogeneity of electrical activation measured within the ischaemic region (Figure 
14). The protective effect of preconditioning on the degree of inhomogeneity disappeared in 
the presence of meclofenamate and L-NAME, whereas the protection was still present 
regarding changes in the epicardial ST-segment elevation, particularly when the drugs were 
given after preconditioning but prior to the prolonged occlusion of the LAD (Figure 13). 
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Figure 13. Changes in epicardial ST segment elevation (mV) during the first and the 
second episodes of preconditioning occlusion, and over a 25 min occlusion of the LAD in 
control, preconditioned dogs (PC), and in dogs in which sodium meclofenamate and L-NAME 
were given either prior to the preconditioning or prior to prolonged occlusion. * P<0.05 vs. 
control group. 
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Figure 14. Changes in the degree of electrical inhomogeneity within the ischaemic area 
during a 25 min occlusion of the LAD in control dogs, in preconditioned dogs (PC), and in 
dogs in which meclofenamate and L-NAME were given either prior to or after 
preconditioning. * P<0.05 vs. control group. 
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3.3. Evidence for the role of nitric oxide in delayed protection induced by right 
ventricular pacing 
3.3.1. Haemodynamic effects of administration of aminoguanidine in paced and unpaced 
dogs 
Aminoguanidine in a dose of 50 mg kg"1 given 30 minutes prior to the pacing stimulus, or 
just prior to the coronary artery occlusion, significantly increased systolic, diastolic and mean 
arterial blood pressure and decreased heart rate. Data are summarised in Table 4. Most of these 
changes returned to the baseline before the commencement of the coronary artery occlusion. 
Table 4. Haemodynamic effects of aminoguanidine (50mg kg'1 ) in dogs 
Time after injection (min) 
Groups Baseline 1 5 15 30 
P+AG 139±6 14119 15718b 15117 14719 
SABP (mmHg) AG+occl 136±7 14017 17615e 161.517e 156110" 
AG+P 18016 18718 19217b 18816a 18817 
P+AG 92±5 9117 11315e 10215 9916 
DABP (mmHg) AG+occl 95±3 9914 12915.5e 11413e 10615" 
AG+P 13813 14415 15113e 14514e 14515a 
P+AG 10715 10717 12816e 118.516 11517 
MABP (mmHg) AG+occl 10914 11315 14516e 13014e 12316" 
AG+P 15214 15816 16514e 15914" 15915a 
P+AG 14619 13918a 13417" 14319 14318 
HR (beats min l) AG+occl 14415 14416 13217e 14512 14818 
AG+P 15214 15816 16514e 15914" 15915a 
Table 4. Changes in the haemodynamic parameters following aminoguanidine given either 
30 min prior to the pacing stimulus (AG+P) or just prior to the coronary artery occlusion in 
paced (P+AG) and in unpaced dogs (AG+occl). SABP: systolic arterial blood pressure 
(mmHg), DABP: diastolic arterial blood pressure (mmHg), MABP: mean arterial blood 
pressure (mmHg), HR: heart rate (beats min1). a: P<0.05 vs. baseline, b: P<0.01 vs. 
baseline, c: P<0.001 vs. baseline. 
3.3.2. Delayed protection by right ventricular pacing against ischaemia-reperfusion induced 
arrhythmias 24 h later; effects of aminoguanidine 
Rapid cardiac pacing results in pronounced protection against those ventricular arrhythmias 
which occur during a 25 min occlusion of the left anterior descending coronary artery 24 h 
later. Thus, compared to the sham controls there were significant reductions in the number of 
VPBs (70+28 vs. 330+110, P<0.05) and in the number of episodes of VT (2.2+1.9 vs. 
6.4+3.6) in dogs paced 24 h previously (Figure 15). Right ventricular pacing also protected the 
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heart against life-threatening ventricular arrhythmias which occurred either during occlusion or 
after reperfusion. Thus, compared to the sham control group in which almost 60% of the dogs 
fibrillated during occlusion only 15% of the dogs which were subjected to right ventricular 
pacing 24 h earlier fibrillated during this time. In the control group, 3 out of those dogs which 
survived the LAD occlusion fibrillated after reperfusion. Thus, in this group 2 out of 12 dogs 
survived the combined occlusion-reperfusion insult. In contrast 62% of the dogs survived the 
combined occlusion-reperfusion insult which were paced 24 h before the occlusion (Figure 
16). 
Figure 15. The number of ventricular premature beats (VPBs) and the number of episodes 
of ventricular tachycardia (VT) during coronary artery occlusion in sham control dogs (SC5), 
in dogs paced 24 h previously without aminoguanidine (P) and in paced dogs in which AG 
was given either 30 minutes prior to the pacing stimulus (AG+P) or prior to the occlusion of 
the LAD (P+AG) as well as in unpaced dogs subjected to a 25 min occlusion of the LAD 
(AG+occl). * P<0.05 vs. sham control group, f P<0.05 vs paced group. 
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Figure 16. The incidence of ventricular tachycardia (VT), ventricular fibrillation (VF) and 
survival in sham control dogs (SC5), in dogs paced 24 h before occlusion (P) and in paced 
dogs in which AG was given 30 minutes either prior to the pacing stimulus (AG+P) or prior 
to the occlusion of the LAD (P+AG) as well as in unpaced dogs subjected to 25 min occlusion 
of the LAD (AG+occl). * P<0.05 vs. sham control group, f P<0.05 vs. paced group. 
Administration of aminoguanidine markedly attenuated the antiarrhythmic protection 
resulted from cardiac pacing. Aminoguanidine given either prior to the pacing stimulus or prior 
to the coronary artery occlusion resulted in similar increase in the severity of ventricular 
arrhythmias. The number of VPBs was as high as in the control group (243+67 and 285+120 
in paced dogs given AG prior to pacing and prior to occlusion, respectively, Figure 15). The 
protection against VT and VF during occlusion was lost in the AG treated animals, and only 
17% of the dogs given the drug prior to pacing and 11% of the animals treated with AG before 
occlusion survived the combined ischaemic-reperfusion insult (Figure 16). 
Interestingly, AG given to unpaced dogs 30 minutes prior to coronary artery occlusion 
resulted in a slight reduction, rather than an increase, in the severity of ventricular arrhythmias 
during ischaemia (Figure 15 and 16). 
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3.3.3. Effect of cardiac pacing on epicardial ST-segment elevation and on the degree of 
inhomogeneity of electrical activation; effects of aminoguanidine 
These are illustrated in Figures 17 and 18. Right ventricular pacing 24 h prior to coronary 
artery occlusion significantly reduced the severity of myocardial ischaemia compared to the 
control group as indicated by marked reduction in epicardial ST segment elevation and in the 
degree of electrical inhomogeneity. This protection was reversed by aminoguanidine when it 
was administered in paced dogs either prior to the pacing stimulus or prior to the coronary 
artery occlusion. Aminoguanidine itself did not modify these indices of ischaemia severity in 
unpaced dogs. 
Time (mill) 
— • — SC5— O — Paced — • — AG+P24 — O — P24+AG — • — AG+ocd 
Figure 17. Changes in epicardial ST segment elevation (mV) during myocardial ischaemia 
in sham control (SC5), in dogs paced 24 h before occlusion (P), and in paced dogs treated 
with aminoguanidine 30 minutes either prior to the pacing stimulus (AG+P) or prior to the 
coronary artery occlusion (P+AG), as well as in unpaced dogs subjected to 25 min occlusion 
of the LAD (AG+occl). 
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Figure 18. Changes in the degree of inhomogeneity of electrical activation during 25 min 
occlusion of the LAD in sham control (SC5),in dogs paced 24 h before occlusion (P), and in 
paced dogs treated with aminoguanidine 30 min either prior to pacing (AG+P) or prior to 
occlusion (P+AG), as well as in unpaced dogs (AG+occl). 
3.4. Evidence for the role of nitric oxide in delayed protection induced by repeated 
pacing; effect of AEST on ventricular arrhythmias and on severity of myocardial 
ischaemia 
There was no changes in haemodynamic parameters during infusion of AEST (data not 
shown). 
As it was demonstrated in Figures 6 and 7 repeated cardiac pacing prolonged the protection 
against ischaemia and reperfusion-induced ventricular arrhythmias. Thus, compared to the 
sham controls (SC3), 72 h after the second pacing stimulus the number of VPBs (101±49 vs. 
229±94, Figure 19) and the number of episodes of VT (1.6+1.5 vs. 3.9±2.1, Figure 19) were 
decreased. This protection against VPBs and VT episodes was largely attenuated when AEST, 
a reasonably selective inhibitor of the iNOS, was given prior to coronary artery occlusion. In 
these dogs the number of VPBs (237±98) and VT episodes (5.6±2.7) was markedly increased 
(Figure 19). 
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Figure 19. The number of ventricular premature beats (VPBs) and the number of episodes 
of ventricular tachycardia (VT) during coronary artery occlusion in sham control dogs (SC3), 
in dogs subjected to repeated pacing 72 h previously (PP72), in repeatedly paced dogs given 
AEST 90 minutes prior to the pacing stimulus (RP72+AEST) and in unpaced dogs treated 
with AEST prior to occlusion of the LAD (AEST+occl). 
VT VF VF Survival 
OCCLUSION OCCLUSION-REPERFUSION 
• SC3 DRP72 H RP72+AEST • AEST+occl 
Figure 20. The incidences of ventricular tachycardia (VT) and ventricular fibrillation (VF) 
and survival from the combined ischaemia-reperfusion insult in sham control dogs (SC3'), in 
dogs subjected to repeated pacing 72h previously (BP 72), in dogs repeatedly paced and given 
AEST 90 min prior to the pacing stimulus (RP72+AEST), and in unpaced dogs treated with 
AEST prior to occlusion of the LAD (AEST+occl). *: P<0.05 vs. RP72+AEST, +: P<0.05 vs. 
SC3. 
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Similarly, compared to the control group, repeated pacing significantly reduced the 
incidence of VT (18% vs. 60%, P<0.05) during occlusion and the incidence of VF (27% vs. 
70%, P<0.05) after reperfusion (Figure 20). Thus, survival from the combined occlusion-
reperfusion insult was 30% in the sham controls and 73% in dogs paced repeatedly. AEST 
given prior to coronary artery occlusion in paced dogs increased the incidences of VT (to 
63%), and VF (to 63%) during occlusion and also following reperfusion (88%). Thus, only 
one dog out of 8 survived in this group. AEST itself did not significantly modify the severity of 
ventricular arrhythmias (Figures 19 and 20). 
Repeated cardiac pacing significantly reduced the severity of myocardial ischaemia 
compared to the sham control group as shown by the marked decrease in epicardial ST-
segment elevation and in the degree of inhomogeneity. Administration of AEST prior to 
occlusion of the LAD in repeatedly paced dogs abolished this protective effect; ie. there was a 
rapid development in epicardial ST-segment elevation and in the degree of inhomogeneity. 
These changes were similar to that observed in the sham controls (Figure 21). 
SC3 - O - RP72 - • - RP72+AEST - • - AEST+occl 
Figure 21. Changes in epicardial ST-segment elevation and degree of inhomogeneity in 
sham control dogs (SC3), in dogs paced repeatedly (RP72), in repeatedly paced dogs treated 
with AEST (RP72+AEST) and in unpaced dogs given AEST prior to occlusion (AEST+occl). 
* P<0.05. 
3.5. Evidence that the inducible form of nitric oxide synthase plays a role in the delayed 
cardioprotection 
3.5.1. Electromobility shift assay for the measurement of activation of nuclear factor K-B 
Activation of nuclear factor K-B (NFKB) was analyzed by electromobility shift assay, a 
method used to detect the phosphorylated transcription factor in the nucleus by means of 
radioactive labelled specific oligonucleotide. The active transcription factor constitutes a 
homodimer or heterodimer from two different subunits (p65 and p50). 
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There was a small constitutive activity of the p65, but not of the p50, subunit in the rabbit 
and dog sham controls. In rabbits 10 min after ischaemic preconditioning both p50 and p65 
subunits of the N F K B were already activated (approximately twice more compared to the 
sham control). Interestingly, NFKB starts to lose its activation 1 h after ischaemic 
preconditioning. At this time the p65 subunit was still activated and this activation was nearly 
completely lost after 3 h recovery (Figure 22). Although in rabbits slight activation was still 
apparent in p65 subunit 1 or 3 h following the preconditioning stimulus, the activation of the 
p50 subunit was markedly attenuated by that time. 
Preconditioning induced by rapid cardiac pacing in dogs resulted in a very strong activation 
of the p65 subunit (approximately four times more than in the controls, Figure 22). Compared 
to the rabbits there was a shift in the time course of the activation of p65; the most 
pronounced activation of the factor was seen 1 h after cardiac pacing, a time when the 
antiarrhythmic protection has already faded. In dogs neither the p65 nor the p50 subunit of 
NFKB was activated 15 min or 24 h after pacing (Figure 22) . 
Figure 22. Electromobility shift assay to measure activation of p65 and p50 subunits in 
dogs paced 15 min, 1 h or 24 h previously and in rabbits preconditioned 10 min, 1 h and 3 h 
previously, and in the sham controls. 
4. Discussion 
4.1. Time course of delayed cardioprotection induced by preconditioning 
It is well established that preconditioning induced either by short coronary artery occlusions 
or rapid cardiac pacing produces both early and delayed protection against severe 
consequences of myocardial ischaemia such as myocardial infarction and life-threatening 
ventricular arrhythmias. The degree of both these phases of the protection depends on the 
strength of preconditioning (i.e. the duration and the number of the preconditioning stimulus). 
For example, in rabbits four episodes of total coronary artery occlusion (total 20 min severe 
ischaemia) protects the heart against ischaemic damage which lasts for 72 h (44). In the same 
species 10 episodes of 5 min cardiac pacing, which probably does not result in as severe 
ischaemia as coronary artery occlusion, results in cardioprotection for 48 hours (35). In dogs 
four 5 min episodes of cardiac pacing through the right ventricle protects the heart against 
ventricular arrhythmias resulting from a subsequent coronary artery occlusion and reperfbsion. 
This protection is apparent 24 h after pacing but fades by 48 h and is lost 72 h later (30). 
However, our experiments demonstrated if we repeat the pacing stimulus at a time when the 
antiarrhythmic effect of the previous pacing was virtually lost (i.e. at 48 h) the protection 
against these severe ventricular arrhythmias can be extended for a longer period. Thus, 48 h 
and 72 h after the second pacing stimulus the antiarrhythmic protection is still present (70). 
This protection starts to disappear 96 h after repeated pacing (70). 
Prolonged delayed protection against myocardial infarction could be induced by repeated 
administration of 2-chloro-N6-cyclopenthyl-adenosine (CCPA), an Ai adenosine receptor 
agonist (71). Given this drug at 48 h intervals for 10 days significantly reduced the extent of 
necrosis 48 h after the last bolus injection of the drug (71). Although this study did not attempt 
to examine the time course of the protection it can be assumed that this protective effect 
induced by repeated administration of CCPA lasts longer. However, as Hashimi and colleagues 
have pointed out chronic administration of an Ai agonist could result in tachyphylaxis and loss 
of protection perhaps by downregulation or desensitization of Ai receptors (72). 
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4.2. Possible mechanisms involved in the early phase of protection 
Although the precise mechanisms of ischaemic preconditioning are not well established 
there is great deal of evidence that endogenous protective substances, released either from 
cardiac myocytes or vascular endothelial cells, or both, contribute to an adaptation associated 
with ischaemic preconditioning (47, 73, 74). It seems very likely that the early cardioprotection 
against ventricular arrhythmias in the canine heart induced either by short coronary artery 
occlusions or by cardiac pacing involves similar trigger mechanisms and mediators such as 
bradykinin, nitric oxide and prostacyclin (6, 56, 57, 60, 63-65, 75). 
Previous studies have demonstrated that both prostacyclin and nitric oxide play an important 
role in the mechanism of protection against ventricular arrhythmias resulting from coronary 
artery occlusion and reperfusion (6, 47, 73, 74). Inhibition of cyclooxygenase and nitric oxide 
synthase enzymes with meclofenamate and with L-NAME, respectively, markedly attenuates 
the antiarrhythmic effects of ischaemic preconditioning in anaesthetised dogs (6, 63). When 
these inhibitors were administered simultaneously prior to preconditioning the protection 
against ventricular arrhythmias was completely abolished (76). Moreover it was difficult even 
to precondition the dogs when these endogenous pathways were simultaneously blocked 
(Figure 10). 
There is substantial evidence that bradykinin triggers the generation of prostacyclin and 
nitric oxide (61, 62, 65). Local intracoronary infusion of bradykinin before coronary artery 
occlusion in dogs results in a significant reduction in the severity of myocardial ischaemia 
(reduced ST-segment elevation and degree of inhomogeneity of electrical activation) and 
suppresses ventricular arrhythmias (56). Furthermore, the protective effect of preconditioning 
against ventricular arrhythmias is abolished by icatibant, indicating the involvement of 
bradykinin and the subsequent activation of bradykinin B2 receptors as a consequence of 
preconditioning (57, 77, 78). Bradykinin also plays a trigger role in the protective effect of 
preconditioning against ischaemic damage. Intravenous infusion of bradykinin significantly 
reduces the extension of myocardial infarction and this is prevented by icatibant (58, 59). 
Bradykinin has been found to inhibit noradrenaline release from nerve endings by activating Bi 
receptors; this may contribute to the suppression of phase lb arrhythmias during occlusion 
(79). 
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Figure 23. Hypothesis for the role of endogenous myocardial protective substances in the 
mechanism of the early antiarrhythmic protection induced by preconditioning in the canine 
myocardium. 
On the basis of these findings described above, a possible hypothesis for the mechanism of 
the antiarrhythmic protection might be that bradykinin generated during the early phase of 
ischaemia activates the B2 receptors in the endothelial cells and triggers the generation of 
prostacyclin and nitric oxide from the endothelium (and possibly also from cardiac myocytes). 
One mechanism for this protection might be the elevation of cGMP level as a result of 
activated soluble guanylate cyclase by nitric oxide. This would depress myocardial contractility 
and reduce oxygen demand during ischaemia, perhaps by limiting myocardial cAMP level by 
stimulation of the cGMP dependent phosphodiesterase enzyme. The increased level of cGMP 
can also inhibit L-type Ca2+ channels in the cardiac myocytes (Figure 23). 
There is also some evidence that bradykinin, like adenosine, can translocate protein kinase 
C (PKC) from the cytosol into the cell membrane (and nuclear membrane) where it then 
phosphorylates membrane protein perhaps linked to ATP-dependent potassium channels. In 
theory opening of these channels should be cardioprotective by shortening the action potential 
and reducing the entry of calcium, a key player both in ischaemic damage and generation of 
arrhythmias. 
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4.3. Possible mechanisms involved in the delayed phase of protection induced by 
preconditioning 
The mechanisms of delayed cardioprotection are less well established. The first study which 
suggested that nitric oxide may play a role in this delayed phase of protection was one in which 
dexamethasone given prior to cardiac pacing prevented the delayed antiarrhythmic protection 
in dogs when the coronary artery was occluded 24h later (41). This study indicated that either 
the inducible form of nitric oxide synthase or cyclooxygenase-2, or perhaps both, are involved 
in this protection. A study by Wu and colleagues supports the concept of a role for NO 
generated through activation of iNOS in delayed protection against ventricular arrhythmias. 
They have shown that dexamethasone markedly attenuated the endotoxin-induced 
antiarrhythmic protection in perfused rat hearts subjected to global ischaemia 24h later (80). 
Our experiments, in which selective inhibitors of iNOS (aminoguanidine or AEST) were 
used, also support the hypothesis that delayed antiarrhythmic protection might be mediated, at 
least in part, by nitric oxide most probably generated by iNOS. The protection induced by 
cardiac pacing against ventricular arrhytmias was attenuated in dogs which had been subjected 
to one or two periods of pacing by aminoguanidine (81) or AEST (70). Although the 
protection is most probably due to induction or enhanced activation of iNOS we cannot 
exclude the involvement of the constitutive form of nitric oxide synthase in this phase of the 
protection. This is likely since in our studies administration of aminoguanidine given either 
prior to pacing or coronary artery occlusion resulted in an immediate elevation in arterial blood 
pressure presumably due to inhibition of cNOS (81). There is some evidence that during 
exercise excess generation of nitric oxide results from the upregulation of cNOS (82). 
Imagawa and his co-workers have shown that in anaesthetised rabbits nitric oxide plays a role 
as a mediator of the delayed preconditioning induced by brief coronary artery occlusions (83). 
The delayed protection against ischaemic damage was abolished by the prior administration of 
aminoguanidine. Bolli and his colleagues have described the late effect of ischaemic 
preconditioning against myocardial stunning in pigs (45) and later in rabbits (84). The authors 
suggest that NO triggers, and also mediates, the late effect of ischaemic preconditioning against 
myocardial stunning. 
Long-term protection of the myocardium can also be evoked by a single dose of 
monophosphoryl lipid A (MLA), a nontoxic derivative of Salmonella thyphimurium endotoxin. 
MLA provides protection against necrosis, contractile dysfunction, ventricular arrhythmias and 
ischaemia-reperfusion injury (85-93). It seems to be likely that the cardioprotective effects of 
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MLA involves myocardial iNOS enzyme activation (90) which can be blocked by 
aminoguanidine (91). The involvement of iNOS with subsequent activation of myocardial 
K+ATP channels (86) is also purposed. 
Delayed protection of the myocardium possibly requires synthesis of various proteins, and 
several transcriptional pathways are stimulated by preconditioning (94-97). The transcription 
factor which is involved in the expression of iNOS is nuclear factor K-B (NFKB). The 
induction of the iNOS by certain stress stimuli depends on the activation of this transcription 
factor (98). We have examined whether NFKB is activated after rapid cardiac pacing in dogs, 
and in rabbits subjected to ischaemic preconditioning (IP). In dogs right ventricular pacing 
increased the activity of the p65 subunit 1 h later (Figure 21). In rabbits brief episodes of 
coronary artery occlusion resulted in a more rapid activation of NFKB; both p65 and p50 
subunits were activated 10 min after ischaemic preconditioning (Figure 21). This might 
indicate species difference but also that coronary artery occlusion is stronger stimulus for 
evoking the protection than cardiac pacing. In our experiments in the rabbit heart the NFKB 
starts to be downregulated 1 h or 3 h after preconditioning. A similar time course of the 
activation of NFKB has been found in conscious rabbits (99). However, Bolli and his 
colleagues have shown the maximal activity of the factor 30 min after ischaemic 
preconditioning and the downregulation of the factor was seen 2 and 4 h later (99). 
Other hypotheses for the mechanism of delayed cardioprotection suppose "de novo" 
synthesis of cytoprotective proteins such as heat stress proteins (100-102) or antioxidant 
enzymes (103-105). There is strong evidence that the stress proteins, particularly of the hsp70 
and hsp27 families, play an important role in defence mechanisms against ischaemic injury 
(102). These proteins act as molecular chaperones and prevent the denaturation of proteins 
resulting from various stress stimulus in the cells (106). The results of studies which aimed to 
examine the role of antioxidant enzymes such as superoxide dismutase (Mn-SOD) or catalase 
in this protection are controversial. In pigs, the protection against contractile dysfunction 
which is observed 24 h after ischaemic preconditioning was not associated with an increase in 
the protein level, or activity, of antioxidant enzymes (107). However, in cultured rat cardiac 
myocytes hypoxic preconditioning or heat stress resulted in tolerance to sustained ischaemia 24 
h later with a concomitant increase in the level and the activity of Mn-SOD (108, 109). 
Hoshida and colleagues have demonstrated that this delayed protection against ischaemic injury 
was due to enhanced Mn-SOD activity in the canine heart, 24 h after ischaemic 
preconditioning (110). 
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4.4. Clinical relevance of ischaemic preconditioning 
There is no doubt that the powerful protection afforded by preconditioning against the 
severe consequences of a sustained ischaemic episode, such as sudden cardiac death resulting 
from fatal ventricular fibrillation or acute myocardial infarction, has great clinical relevance. 
The fact that short episode of ischaemia can be protective may offer possibilities for the 
treatment of ischaemic heart disease. For example, those patients who have an episode of 
angina (short ischaemia) resulting from ischaemic heart disease prior to myocardial infarction 
have a lower mortality rate and reduced necrosis (111, 112). This phenomenon suggests that 
the human heart can adapt rapidly to an ischaemic stress. One example of preconditioning in 
the human myocardium might be interventions during PTCA. Short episodes of ischaemia 
evoked by repeated balloon inflation resulted in significantly less lactate production and ST-
segment changes and the patients reported less pain (17, 113). 
It is hoped that a more intensive research related to the mechanism of this prolonged 
protection associated with preconditioning will advance our knowledge and understanding of 
this from of cardioadaptation and eventually point to new cardioprotective strategies. 
5. New findings 
1. We have demonstrated for first time that the marked delayed protection of the 
myocardium induced by cardiac pacing, which is very powerful 24 h later but fades 48 h after 
the pacing stimulus, can be extended for a longer time (to 48 h or 72 h). After repeated pacing 
there is a pronounced and extended duration of protection against ischaemia and reperfusion-
induced ventricular arrhythmias; this prolonged protection starts to fade only 96 h after 
repeated pacing. 
2. We have also shown that both nitric oxide and prostacyclin are important mediators of 
the antiarrhythmic protection induced by ischaemic preconditioning. This antiarrhythmic 
protection was completely abolished by simultaneous blockade of L-Arg/nitric oxide and 
cyclooxygenase pathways. 
3. Delayed antiarrhythmic protection induced by single or repeated right ventricular pacing 
may involve an increased nitric oxide production, most probably by the induced form of nitric 
oxide synthase. This is supposed by those experiments in which the protection was markedly 
attenuated after administration of aminoguanidine and AEST, two selective inhibitors of iNOS. 
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4. We have found an increased activity of NFKB, a transcription factor involved in the 
expression of iNOS, 1 h after rapid cardiac pacing and 10 min after ischaemic preconditioning. 
This also supports the hypothesis of the role of iNOS in delayed cardioprotection. 
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